Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.

Autor:	Mac Curtain, Benjamin M., O'Brien, Luke, El Sherif, Omar, Mc Cormack, Aidan, Carolan, Emer, Ryan, John D., O'Shea, Donal, Gallagher, Tom K.
Předmět:	GLUCAGON-like peptide-1 agonists MEDICAL information storage & retrieval systems PATIENT safety HYPOGLYCEMIC agents SURGICAL complications SYSTEMATIC reviews MEDLINE LITERATURE reviews MEDICAL databases DRUG efficacy ONLINE information services LIVER transplantation WEIGHT gain PHARMACODYNAMICS EVALUATION
Zdroj:	Gastroenterology & Hepatology from Bed to Bench; Winter2024, Vol. 17 Issue 1, p17-27, 11p
Abstrakt:	Weight gain post-liver transplant can lead to adverse patient outcomes in the post-transplant period. Pharmacotherapy and other measures can be utilised to reduce the burden and occurrence of weight gain in this population. We explored the mechanism of action, safety, and efficacy of these medications, specifically GLP-1 receptor agonists and metformin, focusing on liver transplant patients. This scoping review was conducted in line with the scoping review structure as outlined by the PRISMA guidelines. Metformin and GLP-1 receptor agonists have been observed to be safe and effective in liver transplant patients. Experimental models have found liver-centric weight loss mechanisms in this drug cohort. There is a paucity of evidence about the use of antihyperglycemics in a post-transplant population for weight loss purposes. However, some small studies have shown strong safety and efficacy data. The evidence in relation to using these medications in patients with metabolic syndrome for weight loss warrants further study in a transplant population. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu